Discover the considerations behind CSL Seqirus' shift to trivalent influenza vaccines, removing B/Yamagata strain. Gregg Sylvester, MD, MPH, explains the impact on effectiveness and steps for a seamless transition in health care facilities.
Influenza virus
(Adobe Stock 190526516 by Axel Kock)
As we navigate the complexities of influenza prevention amidst the ongoing challenges posed by the COVID-19 pandemic, the significance of vaccines in curbing the spread of influenza cannot be overstated.
While practices such as hand hygiene and covering coughs and sneezes remain crucial, vaccines play a pivotal role in bolstering our defenses against seasonal influenza.
In a recent interview with Gregg Sylvester, MD, MPH, chief health officer and vice president of medical affairs at CSL Seqirus, Infection Control Today® (ICT®) discusses the considerations behind the decision to transition from quadrivalent to trivalent influenza vaccines for the upcoming US influenza season.
ICT: What considerations led to the decision to transition from quadrivalent to trivalent influenza vaccines for the upcoming US influenza season?
Gregg Sylvester, MD, MPH, chief health officer and vice president of medical affairs of CSL Seqirus: The World Health Organization's (WHO) comprehensive surveillance system for tracking influenza virus activity detected a decline in B/Yamagata circulation before the onset of the COVID-19 pandemic. Subsequently, the WHO confirmed that no circulation of B/Yamagata lineage viruses had been detected since March 2020.
Considerations leading up to the decision to transition to trivalent included the epidemiology and characteristics of the B/Yamagata strain itself. B/Yamagata has shown a slower mutation rate than other influenza virus strains, tended to appear in more temperate climates, and had already been in decline before the onset of the COVID-19 pandemic.
In February 2024, the WHO reinforced its recommendation that B/Yamagata lineage antigen should be excluded from seasonal influenza vaccines when they made their recommendation for the composition of influenza vaccines for use in the 2024-25 Northern Hemisphere influenza season.
ICT: How does removing the B/Yamagata strain impact the effectiveness of the upcoming trivalent influenza vaccines?
GS: With B/Yamagata no longer detected in circulation, this formulation transition will not impact vaccine effectiveness. Instead, it will deliver vaccines developed to match projected circulating strains based on annual guidance by the FDA in collaboration with several global regulatory bodies.
ICT: Could you explain the process of transitioning the entire portfolio of seasonal influenza vaccines to trivalent formulations?
GS: CSL Seqirus worked closely with the FDA during 2023 to develop plans and agreed on a path forward, which was finalized in December, to remove the B/Yamagata antigen from the influenza vaccine formulation and convert the full US seasonal influenza vaccine portfolio.
As a result of this effort and our swift response to meet the FDA's directive, CSL Seqirus received FDA approval on March 4, 2024, for all of its US trivalent influenza vaccines.
ICT: What steps is CSL Seqirus taking to ensure a smooth transition for health care facilities and providers administering these vaccines?
GS: Understanding the critical role health care providers play in public health, we've proactively communicated these changes to ensure a seamless transition. It's our commitment to keep our partners well-informed, so together we can help safeguard our communities against influenza and its complications.
ICT: Considering this change, what advice do you have for health care professionals to prepare for the 2024-2025 influenza season and optimize influenza vaccination efforts?
GS: As we approach the 2024-2025 flu season, it’s more important than ever to focus on thoughtful education about influenza vaccination. By ramping up education efforts on the importance of influenza vaccination, we strive to increase immunization rates and vaccine confidence to improve public health and alleviate the burden on health care systems.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.